COR ET VASA is a prominent peer-reviewed journal in the field of cardiology and cardiovascular medicine, published by the Czech Society of Cardiology and Czech Society of Cardiovascular Surgery. Established in 1961, and continuing its legacy from 2006 to 2024, this journal serves as an essential platform for disseminating significant research findings, clinical studies, and innovative treatments in cardiovascular health. While currently positioned in the Q4 quartile, the journal aims to enhance its impact by fostering knowledge sharing among researchers, clinicians, and students alike. The journal, with its publication in Czech Republic, provides a unique perspective to the European cardiovascular community, allowing for invaluable insights and discourse. Researchers are encouraged to submit their manuscripts and contribute to the growing body of knowledge in this critical area, although it should be noted that COR ET VASA does not offer open access options at this time. As the field of cardiovascular medicine evolves, COR ET VASA remains committed to addressing the latest challenges and advancements, nurturing a rich dialogue within the community.

Cardiology Journal, published by VIA MEDICA, stands as a prominent resource in the field of cardiology and cardiovascular medicine, with an ISSN of 1897-5593 and an E-ISSN of 1898-018X. Recognized for its Open Access model established since 1994, this journal facilitates widespread dissemination of critical research findings, allowing practitioners and researchers globally to access valuable insights without barriers. Based in Poland, with an address at UL SWIETOKRZYSKA 73, 80-180 GDANSK, it has achieved a respectable Q2 classification in 2023 for both Cardiology and Miscellaneous Medicine categories, reflecting its influence and quality within the scholarly community. With a Scopus ranking placing it at #117 out of 387 in Cardiology, it lies within the 69th percentile, underpinning its commitment to advancing knowledge in cardiovascular health. The journal’s converged years extending from 2006 to 2024 ensure it captures ongoing developments in a rapidly evolving field. As such, the Cardiology Journal serves as an indispensable platform for researchers, professionals, and students dedicated to exploring the frontiers of cardiac science and improving patient care.

International Cardiovascular Research Journal, published by Shiraz University Medical Sciences, serves as a vital platform for the dissemination of cutting-edge research in the field of cardiology and cardiovascular medicine. Since its inception in 2011, this journal has continuously devoted itself to promoting the highest quality of scholarly communication, helping to bridge the gap between laboratory findings and clinical application. With an ISSN of 2251-9130 and an E-ISSN of 2251-9149, it is indexed in prominent databases, contributing to its visibility and accessibility to a global audience. Although currently classified in the Q4 quartile in the 2023 rankings, the journal is committed to enhancing its impact factor and academic stature. It aims to facilitate open access for all published articles, although specific details on access options are pending. Through its rigorous peer-review process and diverse scope—which encapsulates advancements, clinical studies, and innovative therapeutic strategies—this journal fosters academic collaboration in the realm of cardiovascular health, making it an invaluable resource for researchers, practitioners, and students alike.

Cardiovascular Therapeutics is a renowned Open Access journal, published by WILEY-HINDAWI, that has been at the forefront of advancing knowledge in the field of cardiology and cardiovascular medicine since its establishment. With a strong commitment to disseminating high-quality research, the journal has successfully positioned itself within the Q2 quartile in multiple categories, including Cardiology and Cardiovascular Medicine, Medicine (miscellaneous), and Pharmacology. The journal is indexed in Scopus, achieving impressive rankings, such as #95 out of 387 in Cardiology, and #87 out of 272 in Medical Pharmacology. Situated in the United Kingdom, Cardiovascular Therapeutics embraces an Open Access model since 2019, ensuring that groundbreaking research is accessible to researchers, practitioners, and students across the globe. The journal is dedicated to publishing original research articles, reviews, and clinical studies that contribute to the understanding and treatment of cardiovascular diseases, making it an essential resource for those invested in improving patient outcomes and advancing therapeutic strategies in this vital area of medicine.

International Journal of Cardiology Cardiovascular Risk and Prevention is a distinguished Open Access journal published by ELSEVIER, dedicated to advancing research in the realms of cardiology and cardiovascular medicine. With an ISSN of 2772-4875 and based in the Netherlands, this journal has rapidly established itself as a critical resource for academics and practitioners since its inception in 2021. The journal currently holds a respectable impact factor and occupies the Q2 quartile in both Cardiology and Cardiovascular Medicine and Internal Medicine categories, reflecting its commitment to sharing high-quality research. Researchers can take advantage of its open-access model, ensuring that cutting-edge findings are freely available to a global audience. The journal not only covers innovative studies on cardiovascular risk factors and prevention strategies but also aims to facilitate interdisciplinary collaboration. With an ongoing trajectory from 2021 to 2024, the International Journal of Cardiology Cardiovascular Risk and Prevention is poised to remain a pivotal platform for dialogue and discovery in the evolving landscape of cardiovascular health.

Cardiology and Therapy, published by SPRINGER LONDON LTD, is a leading open-access journal dedicated to advancing the field of cardiology and cardiovascular medicine. With an ISSN of 2193-8261 and an E-ISSN of 2193-6544, this esteemed journal has been at the forefront of disseminating high-quality research since its inception in 2012. It has achieved an impressive Q1 ranking in the 2023 Cardiology and Cardiovascular Medicine category, reflecting its commitment to excellence and relevance in the field. Spanning a wide array of topics—from clinical studies to cutting-edge therapeutic interventions—the journal aims to foster knowledge exchange among researchers, clinicians, and healthcare professionals. In addition, its position in the 72nd percentile of Scopus rankings underscores its global impact and contribution to the cardiovascular research community. With open access options, Cardiology and Therapy ensures that its content is widely accessible, promoting the sharing of vital findings that can influence clinical practice and improve patient outcomes.

Journal of Cardiology, published by ELSEVIER, stands as a prominent resource in the field of cardiology and cardiovascular medicine. With a rich history since its inception in 1987, this peer-reviewed journal aims to disseminate cutting-edge research that enhances the understanding and treatment of cardiovascular diseases. Its 2023 ranking places it in the Q2 category within its discipline, reflecting its significance and impact, as evidenced by a Scopus rank of #123 out of 387 journals, positioning it in the 68th percentile of its field. The journal is headquartered in Japan, providing a unique perspective on cardiological advances relevant not only to the Asian continent but also globally. Though it does not currently offer open access, the Journal of Cardiology remains a vital institutional resource for researchers, clinicians, and students seeking to push the boundaries of cardiovascular science and improve patient outcomes.

Cardiovascular Diagnosis and Therapy, an esteemed journal in the field of Cardiology and Cardiovascular Medicine, is published by AME PUBLISHING COMPANY, based in Hong Kong, China. With an ISSN of 2223-3652 and an E-ISSN of 2223-3660, this open-access journal aims to present cutting-edge research that significantly advances diagnostic and therapeutic practices in cardiovascular health. Recognized for its impact, it holds a 2023 category quartile ranking of Q2 and is positioned at rank #124 out of 387 in Scopus, reflecting its noteworthy contribution to medical literature with a percentile of 68th. The journal welcomes contributions that span various aspects of cardiovascular research, including clinical trials, epidemiological studies, and innovative therapeutic approaches, making it a vital resource for researchers, practitioners, and students alike, committed to improving cardiovascular care.

The American Journal of Cardiology is a leading peer-reviewed journal in the field of Cardiology and Cardiovascular Medicine, published by Excerpta Medica Inc-Elsevier Science Inc. Since its inception in 1958, the journal has consistently contributed to the advancement of cardiovascular research, providing a platform for groundbreaking studies and clinical findings that shape modern medical practices. With an impressive impact factor placing it in the Q1 category in its field for 2023, it ranks among the top journals in medicine, with a rank of #155 out of 387 in the Scopus database, reflecting its significance and rigorous editorial standards. The journal is committed to disseminating high-quality research that fosters innovation and enhances clinical outcomes in cardiology. Although it does not provide Open Access options, the American Journal of Cardiology remains an essential resource for researchers, healthcare professionals, and students looking to deepen their understanding of cardiovascular health.

HEART AND VESSELS is a prominent peer-reviewed journal published by SPRINGER, dedicated to advancing the fields of cardiology and cardiovascular medicine. With its ISSN 0910-8327 and E-ISSN 1615-2573, this esteemed journal encompasses a broad range of topics pertinent to heart health, vascular function, and associated therapies, making it an essential resource for researchers, clinicians, and healthcare professionals alike. Based in Japan and operating since 1985, HEART AND VESSELS has consistently maintained a Q2 ranking in the 2023 category quartiles, highlighting its relevance and impact in the cardio domain. Although it does not offer open access, the journal ensures high-quality publications that contribute significantly to the academic and clinical understanding of cardiovascular health. With over three decades of continuous scholarly contribution, HEART AND VESSELS serves as a vital platform for disseminating cutting-edge research and fostering innovative practices in the management of cardiovascular diseases.